Global Investor Forum Contact

Kees Been

CEO, Lysosomal Therapeutics Inc.


18:30 - 21:00
Keynote VIP CEO-Investor Dinner

Kees is CEO of Lysosomal Therapeutics Inc (LTI), a biotech company focused on probing the lysosomal enzyme system for new drug targets in neurodegenerative diseases. Specifically, it is leveraging the genetic link between Gaucher’s and Parkinson’s disease (PD) to develop compounds that enhance the lysosomal glucocerebrosidase enzyme activity as an entirely new and breakthrough class of agents for the personalized and disease-modifying treatment in PD. The company is currently working toward an exit as part of its option-to-buy collaboration with Allergan. He was formerly CEO of EnVivo Pharmaceuticals (changed to FORUM Pharmaceuticals) for eight years working on cognition drugs for Alzheimer's and schizophrenia. He spent four years at Biogen, where he directed the Oncology Business Unit which was sold to Idec, and was head of Business Development.
Kees holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering. Kees likes to spend his weekend mornings flying his single-engine airplane, exploring local airports in the New England area that offer brunch menus


Lysosomal Therapeutics, a journey of discovery
Niels Chavannes
Maarten van Dongen
Ingmar de Gooijer
Mark van Houdenhoven
Sint Maartenskliniek

Henk van Houten

Arthur Lahr
Kiadis Pharma

Jos Malda
UMC Utrecht
Eveliene Manten-Horst
AYA Jongvolwassen & Kanker

Madelon Maurice
UMC Utrecht

Tom Miller
GreyBird Ventures
Edwin Moses
Kees Recourt
Mibiton Foundation

Maurits van Selms

Marianne van der Steen
Markwin Velders
Kite Pharma
Werner Verbiest
Janssen Diagnostics
Eline Vrijland-van Beest
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Gold sponsor
Award sponsor
Your logo?
© 2018 Innovation for Health